Setmelanotide was associated with significant weight reduction among patients aged 4 years and older with acquired hypothalamic obesity.

Osteoporosis treatment was associated with reduced hospitalization and mortality risks following fragility fracture after 80 years of age.

Hormone therapy as an adjunctive to tirzepatide was associated with greater weight loss than tirzepatide alone among postmenopausal women.

COCPs were associated with improved obesity outcomes among patients with hyperandrogenic PCOS, but metformin added little benefit.

PCOS was associated with an increased risk for vascular events including stroke among women with thrombotic disease, and a lower mean age.